Molybdenum Cofactor Deficiency Type A Mocod A Epidemiology Forecast

DelveInsight’s ‘Molybdenum Cofactor Deficiency Type A (MoCoD-A) - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Molybdenum Cofactor Deficiency Type A (MoCoD-A), historical and forecasted epidemiology as well as the Molybdenum Cofactor Deficiency Type A (MoCoD-A) epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Disease Understanding

Molybdenum cofactor deficiency (MoCoD-A) is a severe autosomal recessive inborn error of metabolism characterized by neonatal presentation of intractable seizures, feeding difficulties, developmental delays, microcephaly with brain atrophy and coarse facial features.

 

MoCoD-A is caused by homozygous or compound heterozygous mutation in the MOCS1 gene on chromosome 6p21 due to which patients cannot produce a substance known as cyclic pyranopterin monophosphate (cPMP). This results in deficiency of the molybdenum cofactor dependent enzymes sulfite oxidase, xanthine dehydrogenase, aldehyde oxidase and mitochondrial amidoxime reducing component.

 

The resultant accumulation of sulfite, taurine, S-sulfocysteine and thiosulfate contributes to the severe neurological impairment. Most patients die in early childhood from infections. The resultant accumulation of sulfite, taurine, S-sulfocysteine and thiosulfate contributes to the severe neurological impairment. Most patients die in early childhood from infections.

 

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Diagnosis

The diagnosis of molybdenum cofactor deficiency is established by identification of biallelic mutation in MOCS1 by detecting elevated sulfites (in urine test), elevated S-sulfocysteine (in urine test), low uric acid (in blood or urine test) and high levels of xanthine and hypoxanthine (in blood test). Finally, genetic testing confirms the diagnosis and type of MoCoD.

Continued in the report…..

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent population of MoCoD, total diagnosed prevalent population of MoCoD and type-specific diagnosed prevalence of MoCoD covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Molybdenum Cofactor Deficiency Type A (MoCoD-A) Detailed Epidemiology Segmentation

  • As per the assessment of DelveInsight, the total prevalent population of Molybdenum Cofactor Deficiency (MoCoD) in the 7MM was found to be 242 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 0.22% during the study period.
  • In the 7MM, the diagnosed prevalent cases of Molybdenum Cofactor Deficiency (MoCoD) were 49 in 2021. Out of these cases, the United States accounted for about 51% (25 cases) of the total diagnosed prevalent cases among the 7MM, in 2021.
  • There are three forms of MoCoD named types A, B, and C. Molybdenum cofactor deficiency type-A (MoCoD-A) is the most common form and the only one for which there is definitive therapy that improves outcome. In 2021, the total diagnosed prevalent cases of MoCoD-A in the US was 16.
  • Among the European countries, Germany, France, and the UK had the highest diagnosed prevalent population of MoCoD-A with three cases each, in 2021. On the other hand, Spain had only one reported case in 2021.
  • In 2021, Japan accounted for three cases of MoCoD-A. These cases are have decreased from previous years and is expected to increase during forecast period (2022-2032) as the decreasing crude birth rate is compensated by the expected increase in the diagnosis rate.

Scope of the Report

  • The report covers the descriptive overview of Molybdenum Cofactor Deficiency Type A (MoCoD-A), explaining its symptoms, etiology, pathogenesis, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of Molybdenum Cofactor Deficiency Type A (MoCoD-A).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM as the prevalent population of MoCoD, diagnosed prevalent population of MoCoD, and type-specific diagnosed prevalent population of MoCoD).

Report Highlights

  • 11-Year Forecast of Molybdenum Cofactor Deficiency Type A (MoCoD-A)
  • 7MM Coverage
  • Total Prevalent Population of MoCoD
  • Total Diagnosed Prevalent Population of MoCoD
  • Type-specific Diagnosed Prevalence of MoCoD

Key Questions Answered

  • What are the disease risk and burdens of Molybdenum Cofactor Deficiency Type A (MoCoD-A)?
  • What is the historical Molybdenum Cofactor Deficiency Type A (MoCoD-A) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Molybdenum Cofactor Deficiency Type A (MoCoD-A) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Molybdenum Cofactor Deficiency Type A (MoCoD-A)?
  • Out of the above-mentioned countries, which country would have the highest patient population of Molybdenum Cofactor Deficiency Type A (MoCoD-A) during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy

The Molybdenum Cofactor Deficiency Type A (MoCoD-A) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Molybdenum Cofactor Deficiency Type A (MoCoD-A) epidemiology forecast.
  • The Molybdenum Cofactor Deficiency Type A (MoCoD-A) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Molybdenum Cofactor Deficiency Type A (MoCoD-A) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Molybdenum Cofactor Deficiency Type-A Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Molybdenum Cofactor Deficiency Type-A in 2019

3.2. Patient Share (%) Distribution of Molybdenum Cofactor Deficiency Type-A in 2032

4. Executive Summary of Molybdenum Cofactor Deficiency Type-A

5. Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification

5.4. Causes

5.5. Pathophysiology

5.6. Diagnosis

5.5. Genetic Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Assumptions and Rationale: 7MM

6.3.1. The United States

6.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)

6.3.3. Japan

6.4. Total Prevalent Population of Molybdenum Cofactor Deficiency in the 7MM

6.5. Total Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency the 7MM

6.6. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in the 7MM

6.7. The United States

6.7.1. Prevalent cases of Molybdenum Cofactor Deficiency in the United States

6.7.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in the United States

6.7.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in the United States

6.8. EU-5

6.8.1. Prevalent cases of Molybdenum Cofactor Deficiency in the EU-5

6.8.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in the EU-5

6.8.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in the EU-5

6.9. Germany

6.9.1. Prevalent cases of Molybdenum Cofactor Deficiency in Germany

6.9.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in Germany

6.9.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in Germany

6.10. France

6.10.1. Prevalent cases of Molybdenum Cofactor Deficiency in France

6.10.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in France

6.10.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in France

6.11. Italy

6.11.1. Prevalent cases of Molybdenum Cofactor Deficiency in Italy

6.11.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in Italy

6.11.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in Italy

6.12. Spain

6.12.1. Prevalent cases of Molybdenum Cofactor Deficiency in Spain

6.12.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in Spain

6.12.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in Spain

6.13. United Kingdom

6.13.1. Prevalent cases of Molybdenum Cofactor Deficiency in the UK

6.13.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in the UK

6.13.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in the UK

6.14. Japan

6.14.1. Prevalent cases of Molybdenum Cofactor Deficiency in Japan

6.14.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in Japan

6.14.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in Japan

7. Key Opinion Leaders’ Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Epidemiology (2019–2032)

Table 2: Total Prevalent Cases of MoCoD in the 7MM (2019–2032)

Table 3: Total Diagnosed Prevalent Cases of MoCoD in the 7MM (2019–2032)

Table 4: Type-specific Diagnosed Prevalent Cases of MoCoD in the 7MM (2019–2032)

Table 5: Prevalent cases of MoCoD in the United States (2019–2032)

Table 6: Diagnosed Prevalent Population of MoCoD in the United States (2019–2032)

Table 7: Type-specific Diagnosed Prevalence of MoCoD in the United States (2019–2032)

Table 8: Prevalent cases of MoCoD in the EU-5 (2019–2032)

Table 9: Diagnosed Prevalent Population of MoCoD in the EU-5 (2019–2032)

Table 10: Type-specific Diagnosed Prevalence of MoCoD in the EU-5 (2019–2032)

Table 11: Prevalent cases of MoCoD in Japan (2019–2032)

Table 12: Diagnosed Prevalent Population of MoCoD in Japan (2019–2032)

Table 13: Type-specific Diagnosed Prevalence of MoCoD in Japan (2019–2032)

List of Figures

Figure 1: MoCo biosynthesis

Figure 2: Type of MoCoD

Figure 3: Signs and Symptoms

Figure 4: Classification of MoCoD

Figure 5: Biosynthesis of MoCo via an ancient pathway

Figure 6: Alternative splicing of the MOCS1 transcript

Figure 7: Total Prevalent Cases of MoCoD in the 7MM (2019–2032)

Figure 8: Total Diagnosed Prevalent Cases of MoCoD in the 7MM (2019–2032)

Figure 9: Type-specific Diagnosed Prevalent Cases of MoCoD in the 7MM (2019–2032)

Figure 10: Prevalent cases of MoCoD in the United States (2019–2032)

Figure 11: Diagnosed Prevalent Population of MoCoD in the United States (2019–2032)

Figure 12: Type-specific Diagnosed Prevalence of MoCoD in the United States (2019–2032)

Figure 13: Prevalent cases of MoCoD in the EU-5 (2019–2032)

Figure 14: Diagnosed Prevalent Population of MoCoD in the EU-5 (2019–2032)

Figure 15: Type-specific Diagnosed Prevalence of MoCoD in the EU-5 (2019–2032)

Figure 16: Prevalent cases of MoCoD in Japan (2019–2032)

Figure 17: Diagnosed Prevalent Population of MoCoD in Japan (2019–2032)

Figure 18: Type-specific Diagnosed Prevalence of MoCoD in Japan (2019–2032)

Forward to Friend

Need A Quote